Prostate cancer inhibitory activity of a novel dual inhibitor, EL102, in combination with docetaxel, and its effects on MDR1-mediated drug resistance in vitro.

FRANK SULLIVAN

Prostate cancer inhibitory activity of a novel dual inhibitor, EL102, in combination with docetaxel, and its effects on MDR1-mediated drug resistance in vitro.

FRANK SULLIVAN

Medicine

Research output: Chapter in Book or Conference Publication/Proceeding › Conference Publication › peer-review

Original language	English (Ireland)
Title of host publication	48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Place of Publication	Chicago, IL, USA
Publication status	Published - 1 May 2012

Authors (Note for portal: view the doc link for the full list of authors)

Authors
Glynn, SA; Toner, A; Lewis, J; Sullivan, F; Breen, L; Clynes, M; Giles, FJ

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@inproceedings{44e8d6d4cacc4726bccd983e1e684c40,

title = "Prostate cancer inhibitory activity of a novel dual inhibitor, EL102, in combination with docetaxel, and its effects on MDR1-mediated drug resistance in vitro.",

author = "FRANK SULLIVAN",

year = "2012",

month = may,

day = "1",

language = "English (Ireland)",

booktitle = "48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)",

}

Prostate cancer inhibitory activity of a novel dual inhibitor, EL102, in combination with docetaxel, and its effects on MDR1-mediated drug resistance in vitro. / SULLIVAN, FRANK.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL, USA, 2012.

Research output: Chapter in Book or Conference Publication/Proceeding › Conference Publication › peer-review